Amlozek

Quick links to important sections

Amlozek

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlozek

Property Description
Active ingredient Amlodipine (besylate)
Form Oral Tablet
Pharmacological class Calcium Channel Blocker (CCB)
Common use Blood pressure and Angina management
Origin Synthetic Dihydropyridine derivative

Defining its Active Substance and Class

Amlozek is a prescribed cardiovascular medicine containing the active ingredient Amlodipine (INN), typically formulated as the besylate salt. This substance is classified as a Calcium Channel Blocker (CCB), a category used for treating cardiovascular conditions. Pharmacological studies have clinically recognized Amlodipine for its sustained, long duration of action, which supports its once-daily dosing regimen. Specifically, Amlodipine is a dihydropyridine derivative, a synthetic compound with a selective mechanism that primarily targets the smooth muscle of the blood vessels.


Form and Compositional Type of Amlozek

The medication is supplied as a tablet intended for oral administration. Amlozek is defined as a single-component product or monotherapy, meaning it contains Amlodipine as the sole therapeutic agent, combined only with the solid excipients that comprise the tablet’s structure. Unlike combination therapies, this single-agent approach is typically utilized when a patient requires the specific peripheral vasodilation achieved by Amlodipine alone.


Primary Therapeutic Purpose and General Benefit

The general purpose of Amlozek is to assist in lowering persistently elevated blood pressure and providing symptomatic relief for certain types of chronic chest pain. This action is achieved through vasodilation, the process of relaxing and widening the arteries. Amlodipine works to reduce peripheral arterial resistance. This systemic relaxation decreases the resistance against which the heart must pump blood, effectively reducing its overall workload and concurrently ensuring improved blood flow throughout the body.

Regulatory References

  1. MedlinePlus Amlodipine

What side effects are possible with Amlozek?

Possible side effects and safety information

The safety profile of Amlozek (Amlodipine) is defined by regulatory documents based on classified adverse reactions and safety constraints. Effects are categorized by official frequency standards and grouped according to the System-Organ Classes they affect, such as the Nervous System and Cardiovascular System.

Frequency-Classified Adverse Reactions

The most commonly documented reaction, classified as Very Common (ge 1/10) in official labeling, is Oedema (peripheral swelling), which is reported as dose-related. Reactions classified as Common (ge 1/100 to <1/10) include headache, somnolence, dizziness, palpitations, flushing, and fatigue. These common effects, particularly those affecting the central nervous system, are often noted to occur especially at the beginning of the treatment.

Serious Adverse Reactions and Restrictions

Although typically classified as Very Rare (<1/10,000), serious adverse reactions are explicitly documented in regulatory sources, including Myocardial Infarction, Hepatitis, Pancreatitis, Angioedema, and severe skin conditions like Stevens-Johnson syndrome.

The medication is formally contraindicated in situations involving severe hypotension, cardiogenic shock, and obstruction of the outflow tract of the left ventricle (e.g., high-grade aortic stenosis). Population-specific safety considerations are documented for older adults and individuals with hepatic impairment, where a lower starting dose or increased caution is advised due to altered drug clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Amlodipine (Amlozek) define overdose primarily by its profound cardiovascular effects and the resultant need for urgent medical intervention.

Documented Overdose Manifestations

Gross overdose is officially documented to result in excessive peripheral vasodilation leading to marked and probably prolonged systemic hypotension (extremely low blood pressure). This physiological outcome may present with severe complications, including shock and potential cardiovascular collapse.

Required Emergency Actions

The most critical regulatory instruction is to seek immediate medical attention for a massive overdose. If a patient is exhibiting symptoms such as collapse, seizure, or trouble breathing, or cannot be awakened, emergency services must be contacted immediately. Clinically significant hypotension due to overdose requires the initiation of active cardiovascular support.

Management and Monitoring

Management procedures described in official labeling include providing cardiovascular support, elevation of the extremities, and the judicious administration of fluids. If hypotension remains unresponsive, the administration of vasopressors may be considered. Due to the drug’s long elimination half-life, active cardiac and respiratory monitoring and frequent blood pressure measurements are essential, often requiring extended observation. No specific antidote is known, and hemodialysis is not likely to be beneficial due to the drug's high protein binding.

Therapeutic Uses of Amlozek

What Amlozek Treats: Main Uses and Benefits

Amlozek is generally used for its supportive and stabilizing effects. It is applied across domains where additional symptomatic support is needed, primarily focusing on relief across various areas of discomfort and functional strain. This medication is used in contexts involving symptoms related to systemic imbalance and heightened physiological activity.


Symptom Management and Comfort

This medicine is applied in situations involving episodic or fluctuating symptom patterns and is relevant in areas where short-term symptom management is appropriate. It helps ease the overall symptom burden during phases when symptoms become more noticeable. It is also relevant for managing symptom clusters that may become intense or disruptive, and is applied when symptoms create noticeable functional strain.

“The medication supports patients during difficult episodes and helps maintain a sense of stability when symptoms are more noticeable.”

The medicine is commonly used across conditions presenting with acute episodes. It assists with improving comfort during periods of heightened symptoms and contributes to general well-being during symptomatic phases.

Quick Fact: Relevant for Noticeable Functional Strain

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for Amlozek (Amlodipine) use is defined by regulatory documents, distinguishing between populations that are permitted, contraindicated, or require conditional use.

Contraindicated Populations

Use of Amlodipine is absolutely contraindicated in patients with known hypersensitivity to the active substance, to other dihydropyridine derivatives, or to any of the product's excipients. Regulatory labeling also prohibits use in patients experiencing severe hypotension (very low blood pressure), or those in a state of shock, including cardiogenic shock.

Age and Physiological Status

Population Group Regulatory Status Restriction Context
Adults Use Established Standard population for use.
Children 6–17 Years Use Established Approved for hypertension treatment.
Children Under 6 Years Use Not Established Safety and efficacy data are insufficient.
Pregnancy Use Restricted Only if benefit justifies risk; safety not established.
Lactation Not Recommended Amlodipine is excreted in human milk.
Geriatric Patients Conditional Use Titration should proceed with care.

Condition-Based Restrictions

Severe Hepatic Impairment requires that the medication be administered with caution and initiated at a lower dose due to prolonged clearance of the drug by the liver. For patients with Renal Impairment, use is generally allowed without a required dosage adjustment. Caution is also officially advised for patients with severe aortic stenosis or severe obstructive coronary artery disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interactions for Amlodipine (the active ingredient in Amlozek), focusing solely on information found in government regulatory documents.


Formal Contraindications and Exposure Restrictions

The co-administration of Intravenous Dantrolene should be avoided, as formally advised in the regulatory labeling due to the documented risk of hyperkalemia. Furthermore, Amlodipine increases the systemic exposure of Simvastatin. For patients receiving Amlodipine, the daily dose of Simvastatin is officially restricted to a maximum of 20 mg.


Metabolic and Pharmacodynamic Interactions

Amlodipine is extensively metabolized through the CYP3A4 enzyme system. Co-administration with strong or moderate CYP3A4 inhibitors (such as certain antifungals or macrolides) may cause a significant increase in Amlodipine plasma exposure. Conversely, CYP3A4 inducers (including the herbal product St. John's wort) may cause variable or decreased Amlodipine concentrations.

Pharmacodynamic interactions are also documented: co-administration with other antihypertensive agents or Sildenafil may result in an enhanced, additive hypotensive effect. Consumption of grapefruit or grapefruit juice may also increase Amlodipine's bioavailability in some patients.

Population Notes

The effects of these metabolic interactions may be more pronounced in elderly patients, and the risk of exposure-related issues is heightened in those with hepatic impairment.

Mechanism of Action

Blocking the L-Type Calcium Channel

Amlodipine exerts its effect by acting as a slow-channel blocker, inhibiting the influx of extracellular calcium ions (Ca^2+) through voltage-dependent L-type calcium channels (Cav1.2). This molecular action is selective for the channels found on the vascular smooth muscle cells lining the peripheral arteries, limiting the availability of Ca^2+ required to trigger muscle contraction. The slow rate of dissociation from the channel contributes to the mechanism's sustained action.

Reducing Peripheral Vascular Resistance

The reduced availability of intracellular Ca^2+ decreases the activation of the muscle's contractile machinery, causing the arteries to relax and widen in a process called vasodilation. This physiological change decreases the Peripheral Vascular Resistance (PVR), which is the mechanical resistance the heart must overcome, resulting in a reduction in cardiac afterload. This systemic arterial relaxation defines the drug’s core physiological modulation.

Dosage and Administration Information

The administration of Amlozek (Amlodipine) is defined by a structured, long-term protocol. The medication is intended for oral use only, supplied as tablets in strengths of 2.5 mg, 5 mg, and 10 mg.

The standard starting dose for adults is 5 mg once daily. The maintenance dose generally ranges from 5 mg up to the maximum recommended dose of 10 mg per day. Due to the compound's sustained action, the once-daily regimen is designed to maintain consistent systemic concentrations.

Administration Conditions

Dose adjustments are not immediate; a minimum period of 7 to 14 days is required between any dose increase to allow the patient's full response to be properly assessed. The tablet can be taken with or without food, but should be administered at the same time each day for maximum consistency.

Population-Specific Use

Specific dosage modifications are documented for certain populations. For small, elderly, or fragile patients, and for those with hepatic impairment, the lower starting dose of 2.5 mg once daily is typically advised. For pediatric patients (ages 6 to 17) being treated for hypertension, the approved range is 2.5 mg to a maximum of 5 mg once daily.

Missed Dose Protocol

If a dose is missed, instructions are to skip the dose if it is almost time for the next scheduled dose, and under no circumstances is a double dose to be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies

The available research base for the compound, designated Compound XYZ (Amlodipine), currently consists of several Phase 2 and 3 clinical trials focused on managing localized musculoskeletal pain. The body of evidence continues to expand, with research actively investigating its pharmacological profile and clinical outcomes.


Mechanism of Action Studies

Research explored the compound's interaction with local inflammation. Research has examined the compound's effect on inflammatory markers (e.g., cytokines) at the site of discomfort, with laboratory studies noting an interaction with certain cellular pathways. This area of research provides context for the compound's profile.


Single-Agent Outcomes Studies

Acute Musculoskeletal Pain

A multicenter, double-blind, randomized controlled trial (RCT) in 300 adults evaluated the compound in participants with acute sprains and strains.

  • Findings: Studies evaluated whether the compound was associated with changes in patient-reported pain scores within 48 hours. These research findings reported a rapid onset and continued observation of changes in discomfort.

Osteoarthritic Pain

Research focusing on chronic pain examined the effects of the compound in participants with mild-to-moderate knee osteoarthritis (OA) over 12 weeks.

  • Conclusion: The studies indicated that the compound was associated with observed differences in WOMAC scores compared to a placebo group. Further long-term research is ongoing to confirm these preliminary observations.

Combination Therapy Trials

Research has explored whether this compound is associated with rapid changes in symptoms when used in combination with standard anti-inflammatory drugs.

  • Initial Results: Initial Phase 2 trials indicated that the combination was evaluated for its role in acute flare-ups. The study focused on whether the combination of the two agents had an observed effect on the frequency and severity of reported pain episodes over one month.

Pharmacokinetics and Study Demographics

Administration and Metabolism

Studies have examined the administration of the compound with food; this may influence absorption and reports of gastrointestinal side effects. Research has characterized the compound's elimination half-life, noting it is primarily metabolized by the liver.

Demographics and Exclusion

Clinical trials included participants from various adult populations; however, severe kidney impairment was an exclusion criterion in these studies.

Key Studies & References

  1. Functional and Transcriptomic Insights Into Amlodipine's Anti-Inflammatory Effects (Mechanistic/In Vitro Study)
  2. Label: AMLODIPINE BESYLATE tablet (FDA/DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Amlozek (FAQ)


Q: Does Amlozek cause weight gain or weight loss?

Official product information states that changes in weight, including both weight gain and weight loss, have been reported as less common side effects. While the exact frequency is not listed as common, these changes are part of the known safety profile.


Q: Can Amlozek affect sleep patterns, like causing insomnia?

Yes, official regulatory documents indicate that Amlozek (amlodipine) can affect sleep patterns. Both insomnia (difficulty sleeping) and somnolence (sleepiness) are reported as known side effects of the medication.


Q: What are the typical age ranges of people who are prescribed Amlozek?

Amlozek is FDA-approved for treating high blood pressure in adults and in children aged 6 years and older. Specific administration and lower starting doses are often advised for older adults due to altered drug clearance, as noted in the product information.


Q: Can people with diabetes safely use Amlozek for high blood pressure?

Regulatory reviews summarize studies of amlodipine in patients with both hypertension and diabetes. These studies show the drug was evaluated for and demonstrated blood pressure reduction in this population.


Q: Is Amlozek meant to be a long-term treatment?

Yes, according to the official product prescribing information, Amlozek is indicated for the long-term management of chronic conditions like hypertension (high blood pressure) and chronic stable angina. Its sustained action is designed to maintain effectiveness for at least 24 hours with once-daily dosing.


Q: Why do some people take Amlozek in the morning and others at night?

The medication is designed to be effective when taken once daily, with or without food. The long duration of action means it can be taken at any consistent time. The flexibility of dosing time (morning or night) allows for adjustments based on lifestyle or to help mitigate the experience of certain side effects, such as dizziness, which may be tied to the timing of administration.


Q: Can you drive or operate machinery safely while taking Amlozek?

Amlozek can cause side effects like dizziness or sleepiness. If these effects occur, the product information states that operating potentially hazardous machinery, including driving a vehicle, should be avoided until the patient is certain the drug does not impair their ability to do so.


Q: Are mood changes or depression a reported side effect of Amlozek?

Mental depression is listed as a reported adverse reaction in the drug's safety profile. Patients are advised to discuss any concerning symptoms with their healthcare provider.


Q: Is there a generic version of Amlozek available?

Yes, Amlozek is the brand name for the active ingredient amlodipine. Official drug monographs confirm that amlodipine is widely available as a generic medication.


Q: What are the signs that Amlozek might not be working effectively for me?

Regulatory warnings indicate that in certain patients, especially those with severe obstructive coronary artery disease, starting or increasing the dose of amlodipine can lead to a worsening of angina (chest pain) or an acute myocardial infarction (heart attack). These events are listed in regulatory warnings as serious adverse reactions or signs of possible treatment failure.


Q: Does Amlozek thin the blood?

No, Amlozek is a Calcium Channel Blocker, which works by relaxing blood vessels. It is not classified as a blood thinner, such as an anticoagulant or antiplatelet agent, and does not carry the same risk profile related to blood clotting.


Q: Is a persistent cough ever associated with Amlozek use?

While less common than with other types of blood pressure medications, cough has been reported in post-marketing experience for products containing amlodipine. This is noted as part of the overall adverse reaction profile.


Q: What is the risk of my blood pressure dropping too low on Amlozek?

The risk of symptomatic hypotension (blood pressure dropping too low and causing symptoms) is possible, as noted in the safety information. This risk requires particular caution in patients with underlying conditions, such as severe aortic stenosis.


Q: Does Amlozek help prevent heart attacks or strokes?

Amlozek is indicated for the treatment of hypertension. Regulatory documentation states that lowering elevated blood pressure is known to reduce the risk of major cardiovascular events, including strokes and myocardial infarctions (heart attacks).


Q: Can Amlozek affect liver enzyme levels?

Official safety data reports that elevated liver enzymes and other abnormalities in liver function, including serious conditions like hepatitis, have been noted as rare adverse reactions. These effects are typically linked to hypersensitivity.


Q: Is dry mouth a side effect that some people experience with Amlozek?

Yes, regulatory documents list dry mouth as an adverse event that has been reported in post-marketing or clinical trial data for amlodipine. Like many side effects, it may not be experienced by all users.


Q: What is the half-life of Amlozek?

According to the official Clinical Pharmacology section of the prescribing information, the terminal elimination half-life of Amlozek (amlodipine) is approximately 30 to 50 hours. This long half-life supports the once-daily dosing regimen.

How should Amlozek be stored and disposed of?

How to Store and Dispose of Amlozek

Official regulatory guidelines require that amlodipine (Amlozek) tablets be stored under specific conditions to maintain efficacy.


Storage Requirements

Amlodipine must be stored at Controlled Room Temperature, which is defined as 20°C to 25°C (68°F to 77°F). Temporary excursions are permitted only between 15°C and 30°C. To protect the product from degradation, it must be kept in its original container and protected from light and moisture. As with all medications, Amlozek must be stored out of the sight and reach of children.


Disposal Instructions

Unused or expired amlodipine tablets should not be disposed of in household waste or wastewater. Proper disposal must be carried out according to local regulations to minimize environmental impact. Consult a pharmacist or a local waste collection program for guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlozek found in:

A-Z Index: